Gedeon Richter Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Budapest Hungary (1901)
Status: No NME R&D (1901)

Organization Overview

First Clinical Trial
2007
NCT00488618
First Marketed Drug
2003
fluconazole (diflucan)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Gedeon Richter Ltd. | Gedeon Richter Plc. | Gedeon Richter Slovakia, s.r.o. | GEDEON RICHTER USA | PregLem SA

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenomyosis (Phase 2)

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Bipolar Disorder (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Diabetic Neuropathies (Phase 2)

Disease (Phase 3)

Endometriosis (Phase 2)

Hypertension (Phase 4)

Leiomyoma (Phase 3)

Myofibroma (Phase 3)

Myoma (Phase 3)

Neuralgia (Phase 2)

Polycystic Ovary Syndrome (Phase 4)

Schizophrenia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 39
  • # of Trial APIs: 30